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Mutation of p53 gene plays an important role in astrocytoma carcinogenesis. The mutation process results in p53 
mutant which fails to stop the tumor's cellular proliferation or apoptotic process resulting new cells with persistent 
genetic mutation. p53 mutant expression detected by imunnohistochemistry staining shows the biological behavior of 
tumor cell. Some authors found that p53 protein expression relates to histopathological grading which affects the 
prognosis. However, some studies showed different results. These findings invite debatable subject around p53 mutant 
and histophatological grading. The objective of this study was to prove the correlation between p53 mutant protein 
expression with histophatologic grading in astrocytoma patients. This was an analytic cross-sectional study using 
imunohistochemical staining for p53 mutant expression, conducted from January to August 2005. Data were analyzed 
to find the relation between WHO histopathological grading, age, and sex, and p53 protein expression. The confidence 
interval was a = .05. The results found that 33 astrocytoma patients were operated, with age range from 4 to 62 years 
old, averagely 30.91 years old. Most patients aged between 31-40 years old., predominantly male (male: female = 
60.6% : 39.4%). Histopathological diagnosis mostly was diffuse astrocytoma (WHO grade II) found in 48.5% cases, 
pilocytic astrocytoma (WHO grade III) 30.3%, and Globlastoma multiforme 6.1%. Mild expression of p53 was found in 
WHO grade I. Mild expression of p53 increased to 14 (42.4%) in WHO grade II and 2 patients had severe degree. 
Percentage of patients of WHO grade III showed severe grade of expression increasing to 6 patients (18.2%). In WHO 
grade IV group, there was 1 patient (3.0%) with severe expression and 1 patient with very severe expression. Statistical 
analysis using Spearman correlation test showed that there was a correlation between p53 mutant expression with 
increasing histopathological grading of astrocytoma, p=.001 (p<.0001) with correlation coefficient 0.736. In 
conclusion, there is positive correlation between p53 mutant protein expression and histopathological grading 
(p<.0001; correlation coefficient 0.736), as well as age (p<0.05; correlation coefficient 0.434) 
 
Keywords: Astrocytoma, p53 mutant expression, histopathological grading, immunohistochemistry 
 
Correspondence: Joni Wahyuhadi, Department of Neurosurgery, Airlangga University School of Medicine,  





Astrocytoma is an intracranial neoplasma originating 
from astrocyte neuroepithelial cells, constituting 60% 
from all intracranial primary tumors. Five to seven new 
cases were found in 100,000 populations annually, 
which incidence ratio in male and female of 1.8 : 1 (Hao 
Ding et al. 2000; Gregory & Peter 1990). In Dr Soetomo 
Hospital, Surabaya, between 2002 and 2004 there were 
405 brain tumor patients, and 328 of which were 
subjected to operation. Pathological examination in 29% 
of these or 40 patients revealed astrocytoma (Anab & 
Wahyuhadi 2005). The management of astrocytoma is 
highly affected by acid gradation of histopathological 
grading. WHO divides into three gradings: Grade I 
(Pilocystic Astrocytoma), which is curable with radical 
operation; Grade II (Diffuse Astrocytoma) with survival 
expectancy more than 5 years; Grade III (Anaplastic 
astrocytoma), with survival expectancy of 2 years 
(50%), 5 years (2%) and increased 10% if the patient 
receives radiotherap; and Grade IV (Glioblastoma 
Multiforme) with survival expectancy of 9 months 
(50%), 1.5 years(10%) (Flowers 2000; Greenberg et al. 
1999). The tumor can undertake "upgrading" (to 
become more malignant). The problem is the time and 
the causes of the change remain unknown clearly. A 
theory has been developed that the emergence of the 
tumor results from environmental effect and the 
presence of predisposing genetic abnormality. 
Imbalance between oncogene and gene suppressor play 
an important role. Gene suppressor that has been found 
to have a major role is p53 (Litofsky et al. 1997; Nayak 
et al. 2004). Some studies on the effect of p53 mutant 
on astrocytome progressiveness remain controversial. 
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Litofsky et al., Weixin et al., and Put Ti Noi et al. 
suggest that there is a positive correlation between 
excessive expression of p53 mutant an increased 
astrocytoma gradation. However, Nayak et al. and 
Cunningham et al. found that there was no correlation 
between p53 mutant expression and astrocytoma 
gradation. Since, in addition to these findings, p53 
mutant can be examined immunohistochemically in 
Surabaya, the authors attempted to find whether in 
Surabaya, particularly in Dr Soetomo Hospital, a 
correlation exists between p53 mutant expression and 
astrocytoma gradation. Such study had never been 
conducted previously. The finding of such correlation 




MATERIALS AND METHODS 
 
Observation was conducted at once on variables whose 
events had already occurred. This study used analytic 
observational design. Population comprised all paraffin 
blocs preserved at the Department of Anatomic 
Pathology, which were clinically and 
histopathologically showed the appearance of 
astrocytoma, from January 2002 to August 2005. 
Samples consisted of paraffin blocs from all operated 
patients in Dr Soetomo Hospital, from January 2002 to 
August 2005, who were clinically and 
histopathologically showed astrocytoma and selected 
according to WHO histopathological grading. Samples 
size was 33 samples. The inclusion criteria comprised 
primary tumor, well-preserved astrocytoma paraffin 
bloc dating from January 2002 to August 2005, the 
paraffin blocs are eligible for immunohistochemical 
examination and can be well-read, and the patients 
received no previous radiation therapy or chemotherapy. 
Histopathological diagnosis was the diagnosis obtained 
from examination of astrocytoma preparations with 
Hematoxilin Eosin staining. 
 
Histopathological grading was based on the change of 
cellular shape and characteristics and tissue architecture 
examinaed from HE stained preparations with 
magnification of 100 and 400 times using light 
microscope. The evaluation was classified into: 1. 
Pilocytic Astrocytomas (WHO grade I). 
Histopathological examination revealed no anaplastic 
cells, mild cellularity, absence of mitosis, minimal 
endothelial proliferation, no necrosis, and differential 
transitional zone to normal brain. 2. Diffuse 
astrocytoma (WHO grade II). Histopathogical 
examination revealed well-differentiated fibrillar or 
gemistotic neoplastic astrocyte, a loose structural 
background, and microcystic tumor matrix. Cellularity 
increases sufficiently with atipia nucleus. 3. Anaplastic 
astrocytoma (WHO grade III). Histopathological 
examination revealed increased cellularity, well-
differentiated nucleus atipia, and predominant mitosis 
activity. The mitosis is abnormal. Glioblastoma 
multiforme (WHO grade IV). Histopathological 
examination revealed pleomorphism and poor-
differentiation. Mitotic activity is fast. There are 
microvascular proliferation and/or necrosis. The study 
was carried out at Neurosurgery Outpatient Clinic, 
Neurosurgical wards, and the Department of Anatomic 
Pathology, Dr Soetomo Hospital, for 4 months, from 
August 2004 to November 2005. To analyze correlation 
between the expression of p53 mutant and 
histopathological grading, we used Spearman 
correlation test. To analyze the difference of p53 mutant 
expression in various histopathological grading, we 





From January 2002 to August 2005, there were 32 
definitive operations to astrocytoma tumor patients. 
From those 33 patients, 20 individuals (60.6%) were 
male, and the rest 13 individuals (39.4%) were female. 
The youngest age of the patient was 4 years and the 
oldest was 62 years with averaga age 30.91 years. Most 
of the patients aged 37 years, comprising 3 individuals 
(4.1%) and if grouping according to age interval wa 
smade, most of the patients aged 31-40 years, 
comprising 12 individuals (36.4%). 
 




Specimen was taken from patients who had undergone 
operation. Definitive diagnosis based on histopatho-





1. Sex   
      Male 20 60.6 
      Female 13 39.4 
2. Age   
       Youngest 4 years 
        Oldest 62 years 
      Predominant  37 years 
01 - 10 years 4 12.1 
11 - 20 years 6 18.2 
21 - 30 years 4 12.1 
31 - 40 years 12 36.4 
41 - 50 years 2 6.1 
51 - 60 years 4 12.1 
61 - 70 years 1 3 
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(WHO grade II), consisting of 16 cases (48.5%), while 
the others, Pilocytic Astrocytoma (WHO grade I) was 
cases (15.2%), anaplastik astrocytoma (WHO grade III) 
10 cases (30.3%), glioblastoma multiforme 2 cases 
(6.1%). 
 






1. Specimen   
            Operation 33 100% 
2. PA Diagnosis   
Pilocytic Astrocytoma ( WHO Grade I) 5 15.2 
Diffuse Astrocytoma ( WHO Grade II) 16 48.5 
Anaplastic Astrocytoma ( WHO Grade III ) 10 30.3 
Glioblastoma Multiform (WHO grade IV) 2 6.1 
 
Based on k-means cluster analysis there were four 
category of p53 mutant protein, i.e.: 1. Grade I (mild): if 
the mean (median) of p53 mutant expression = 3; 2. 
Grade II (moderate), if the mean (median) of p53 
mutant expression = 11; 3. Grade III (severe), if the 
mean (median) of p53 mutant expression = 21; and 4. 
Grade IV (very severe), if the mean (median) of p53 
mutant expression = 32. The 33 obtained specimens 
were subjected to immunohistochemical staining. We 
obtained 21 specimens (63.6%) with mild p53 mutant 
expression, 8 with moderate expression (24.2%), 2 with 
severe expression (9.1%), and 1 with very severe 
expression (3%). 
 
Table 3. Results of immunohistochemical staining 
 






1. Grade I   (Mild) 21 63.6 
2. Grade II  (Moderate) 8 24.2 
3. Grade III (Severe) 2 9.1 
4. Grade IV (Very Severe) 1 3.0 
 
Based on differential degree groupings, 5 (15.2%) 
patients with Pilocytic Astrocytoma (WHO grade I) 
showed p53 mutant protein expression grade I (mild) 
expression, while protein expression in mild, severe, 
and very severe degree were absent. In patients with 
diffuse astrocytoma (WHO grade II), 14 patients 
(42.4%) had mild grade expression and 2 patients 
(6.1%) had moderate expression. From 10 patients with 
anaplastic astrocytoma, 2 patients (6.1%) showed mild 
expression, 6 patients (18.2%) had moderate expression 
and 2 patients (6.1%) had severe expression. In patients 
with glioblastoma multiforme (WHO grade IV), the 
expression of grade III (severe) was found in 1 patient 
(3.0%) and 1 patient (3.0%) was found to had grade IV 
(very severe) expression. 
 
Table 4. p53 expression distribution according to the grade of differentiation 
 











1.Grade I  









2. Grade II     







3. Grade III  
    (Severe) 






4. Grade III  
    (Very Severe) 




TOTAL 5 16 10 2 33 
 
From statistical analysis using Pearson's Chi-Square test 
(p = 0.000; p < 0.05), we found different p43 mutant 
protein in various histopathological gradings in 
astrocytoma. Based on the histopathological grading, 
WHO grade I only showed grade I (mild) p53 protein 
expression, while grade II (moderate), grade III (severe) 
and grade IV (very severe) were not obtained. In WHO 
grade II, the grade I p53 expression (moderate) 
increased to 14 (42.4%), and 2 patients (6.1%) were 
found with grade III (severe) expression, which was not 
found in WHO grade I. In WHO grade III, the 
percentage of patients showing grade IV (severe) 
expression increased to 6 patients (18.2%), more than 
that in WHO grade II, which was 2 patients (6.2%). In 
WHO grade IV, there was 1 patient (3.0%) with grade 
IV (severe) and 1 patient (3.0%) with grade IV (very 
severe), in very severe grade was not found in grade I, II 
and III. When we observed each grading, according to 
grade increase, the p53 expression was also found to 
increase. Results of statistical analysis using Spearman 
rho correlation test revealed correlation between p53 
mutant expression and the increase of differentiation 
degree (p = 0.0001) with correlation coefficient 0.736. 
 
Based on the patients' age, it was found that there was 
correlation between age increase and mutant p53 protein 
expression. The older the patient's age, the higher the 
mutant p53 expression. Table 5 also shows correlation 
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between age and the increase of WHO grading. The 
older he age, the higher the WHO grading. 
 
Table 5. Correlation between p53 mutant expression and 
WHO histopathological grading and age. 
 




WHO grading r = 0.736 
p = 0.0001 
 
Age r = 0.434 
p = 0.012 
r = 0.641 
p = 0.0001 
 
The mean of mutant p53 protein expression in men was 
higher than that in women. Results of statistical test 
revealed p = 0.047 (p < 0.05), indicating difference in 
the expression of mutant p53 protein between men and 
women. The histopathological grading in men was also 
higher than that in women, in which the statistical test 
showed p = 0.011 (p < 0.05). After being tested with 
multiple linear regression, it was found that only 
histopathological grading that had effect on the 
expression with correlation strength of 0.545, while sex 










P value Notes 
p53 expression 9.09 + 8.57 4.63 + 3.48 t = 0.047 0.047 Significant 
WHO Grading (%)      
I 2 (10.0 %) 3 (23.1 %) z = -2.550 0.011 Significant 
II 7 (35.0 %) 9 (69.2 %)    
III 9 (45.0 %) 1 ( 7.7 %)    




Table 7. The effect of histopathological grading, age, and sex on the expression of mutant p53 protein 
 
Variables B t value p value Notes 
WHO Grading 6,418 3,855 0.001 S 
Age  4,257E – 02 0.568 0.575 NS 
Sex -0.225 -0.112 0,912 NS 





Figure 1.  Observable tumor cells showing positive expression with mutant p53 protein (black arrow), 
while interrupted blue arrow shows tumor cells without the expression of mutant p53 
protein in astrocytoma tumor of WHO grade III (anaplastic astrocytoma) (T 628/04, 
magnification 400x with Olympus microscope). 
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Figure 2. Positive tumor cells with mutant p53 in nucleus (black arrow) and blue interrupted arrow 
shows no mutant p53 protein expresion from grade IV astrocytoma tumor (glioblastoma 





Figure 3.  Positive tumor cells with mutant p53 in nucleus (black arrow), and blue interrupted arrow 
shows no expression of mutant p53 from grade IV astrocytoma tumor (glioblastoma 





From 33 patients we obtained from January 2002 to 
August 2005, male patients were in higher number than 
female patients, where 60.6% of the patients were male. 
This was different from the retrospective descriptive 
study carried out in four hospitals in Surabaya (Dr 
Soetomo, RKZ, Adi Husada, and Darmo Hospitals). In 
year 2002-2004 most of astrocytoma tumor patients 
were female (56% of the cases) (Anab & Wahyuhadi 
2005). Data from WHO classification of tumors, the 
incidence of astrocytoma tumor in men is higher than in 
women (1.8 : 1). The occurrence of the tumor in men is 
averagely in age 52.2 and women in age 37.2. The older 
the age of the patient, the higher the histopathological 
grading (Kleihues 2000). In this study, the tumor was 
mostly found in patients aged 31-40 years old, with 
mean of 30.91. Most of the patients were admitted at 
WHO grade II (diffuse astocytoma), comprising 48.5% 
of the patients. Data between 2002-2004 revealed 
34.11% of the patients were admitted with WHO grade 
III. This proved that the awareness of the patients about 
their disease is very low, as indicated by remarkable 
number of patiens with grade II and III. From 4 year 
data, we found only 5 patients came with WHO grade I. 
 
Specimens we obtained in this study mostly had diffuse 
astrocytoma (WHO grade II), comprising 48.5%, while 
30.3% were anaplastic astrocytoma (WHO grade III), 
pilocytic astrocytoma (WHO grade I) comprising 
15.2%, and the rest, 6.1% were glioblastoma multiforme 
(WHO grade IV). Nayak et al. (2004) collected 
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histopathological data from 152 patients. They found 
9% pilocytic astrocytoma (WHO grade I), 25% diffuse 
astrocytoma (WHO grade II), 19% anaplastic 
astrocytoma (WHO grade III), 46% glioblastoma 
multiforme (WHO grade IV). The above data shows 
difference in the incidence, particularly the GBM, in 
which this study found only 6.1% GBM patients, while 
Nayak et al. found 46%. The presence of difference in 
such epidemological data in Indonesia and western 
countries indicates, first, that there remains many 
aspects that should be investigated regarding the 
behavior of atrocytoma tumor in Indonesia, and, second, 
there is an advance in the treatment and live expectancy, 
providing more responsibilities to the clinicians in 
treatment follow-up since the patients in Indonesia had 
relatively younger age. 
 
Correlation between mutant p53 expression and 
histopathological grading according to WHO 
 
The higher the histopathological grading, the more p53 
mutation occurs, so that the expression of p53 protein 
becomes higher. From the results of statistical analysis 
using Spearman rho correlation test, it was found that 
there was correlation between mutant p53 expression 
and histopathological grading in astrocytoma tumor (p < 
0.0001) with a high correlation strength and had 
positive value. This study confirmed that of Litofsky et 
al. who found correlation between the increase of 
mutant p53 protein expression and the increase of 
histopathological grading. This suggestion was also 
coined by other authors, such was Weixin et al. and Put-
Ti-Noi et al. (Litofsky et al.  1997; Put-Ti-Noi et al. 
2004; Weixin et al. 2000). 
 
This study also confirmed the suggestion that mutant 
p53 protein does not inhibit proliferation or cell cycle in 
G1 phase, so that DNA damage becomes irreversible 
and mutation becomes fixed in the dividing cells, with 
the result that the cells are lead to malignant 
transformation. Abnormal p53 protein produced by 
mutant p53 gene is also capable in binding normal p53 
gene products and inhibit its function as cell 
proliferation inhibitor (Kumar et al. 2005). Tumor cells 
containing mutant p53 gene will be resistant against 
apoptosis, so that tumor lacking these normal p53 genes 
will have more progressive growth. The capability of 
p53 to control apoptosis as a response against DNA 
damage also has practical implications in cancer 
therapy. Radiation and chemotherapy are two primary 
cancer therapies that have effect to induce DNA damage 
and apoptosis. Tumor cells that remains having normal 
p53 gene are more responsive against therapy than those 
containing mutant p53 (Kumar et al. 2005; Stratton 
1996). 
 
Correlation between mutant p53 expression  
and the patients' age and sex 
 
This study shows that the older the age of the patients, 
the higher the expression of mutant p53 mutant. From 
the result of statistical analysis with Spearman rho 
correlation test, we found a strong correlation r = 0.0434 
with p = 0.012. The age also affected the 
histopathological grading, in which the higher the 
patients' age, the higher the histopathological grading (r 
= 0.641, p=0.0001). Similar results were also reported 
by Flowers et al who found correlation between age 
increase and histopathological grading in which at least 
50% of the patients with GBM had the disease at the 
age of more than 55 years (Flowers 2000). Regarding 
with sex, this study revealed significant correlation 
between sex and p53 expression. From statistical test, 
we obtained the value p = 0.047 (p < 0.05), indicating 
difference in mutant p53 protein in men and women. 
Similarly, the histopathological grading in men was 
higher than in women, with p = 0.011 (p < 0.05). Thus, 
although it can be concluded that the higher the 
histopathological grading, the stronger the mutant p53 
protein expression, the expression of p53 protein cannot 
stand by itself. We cannot use it as a single determinant 
in determining disease prognosis, as it is also affected 
by other factors, such as age, sex, and other factors 





It can be concluded that there is difference in mutant 
p53 expression in each histopathological grading of 
astrocytoma tumor, and there is significant correlation 
between mutant p53 expression and the increase of 
astrocytoma histopathological  grading. The higher the 
grading, the higher the expression of mutant p53. 
Therefore, this study proved that mutant p53 expression 
can be used as genetic-based molecular marker that has 
prognostic value for astrocytoma tumor. The higher the 
expression of mutant p53, the higher the 
histopathological grading, the worse the prognosis. 
Further studies are required to involve larger sample, 
and should be carried out retrospectively in order to 
elaborate the role of mutant p53 expression in 
astrocytoma tumor. Further continuous studies are also 
needed on the correlation between mutant p53 
expression and survival rate as well as on radiotherapy 
and chemotherapy, either neoadjuvant, 
chemosensitivity, or the type that would be given. Since 
various studies on the expression of mutant p53 in 
astrocytoma had given different results, a deeper study 
on factors (receptor, hormonal, age, sex, etc.) affecting 
mutant p53 expression on the emergence of astrocytoma 
maligancy is also needed. 
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